Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyzine SCHEMBL383277 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4491 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4492 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41450 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL491323 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL28290521 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41448 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Etodroxizine SCHEMBL9064076 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Etodroxizine SCHEMBL668191 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL15532242 | 0.98 | DRD3 (0.95) | DRD3HRH1KCNH2CYP2D6USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007055806-A1 | ANTI-EMETIC USES OF (3R,4R)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070099988-A1 | ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS, INC. | 2007-05-03 | — | — | US | claimed |
| US-8637087-B2 | Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids | JB THERAPEUTICS INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20110318425-A1 | TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR, 10aR)- DELTA-8-TETRAHDRAOCANNABINOL-11-OIC ACIDS | CORBUS PHARMACEUTICALS INC. | 2011-12-29 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20080182892-A1 | Treatment of interstitial cystitis using (6aR, 10aR)-delta-8-tetrahydrocannabinol-11-oic acids | INDEVUS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2007055806-A1 | ANTI-EMETIC USES OF (3R,4R)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099988-A1 | ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS, INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007047010-A2 | ANTI-EMETIC USES OF CANNABINOID ANALOGS | INDEVUS PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093519-A1 | ANTI-EMETIC USES OF CANNABINOID ANALOGS | INDEVUS PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2006065793-A9 | TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS INC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006065793-A2 | TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS | INDEVUS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065792-A2 | TREATMENT OF INTERSTITIAL CYSTITIS USING CANNABINOID ANALOGS | INDEVUS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128738-A1 | Treatment of interstitial cystitis using cannabinoid analogs | INDEVUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060128794-A1 | Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids | INDEVUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
| US-4443460-A | ANTIALLERGENS, ANTIHISTAMINES, ANTISPASMODICS, BRONCHODILATORS | UCB, SOCIETE ANONYME (BE) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128738-A1 | Treatment of interstitial cystitis using cannabinoid analogs | CNR1, CNR2, GPR18 | HRH1 332/4885DRD3 888/4885KCNH2 2455/4885 |
| US-20060128794-A1 | Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids | CNR1, CNR2, GPR18 | HRH1 412/4885DRD3 778/4885KCNH2 2013/4885 |
| US-20080182892-A1 | Treatment of interstitial cystitis using (6aR, 10aR)-delta-8-tetrahydrocannabinol-11-oic acids | CNR1, CNR2, GPR18 | HRH1 434/4885DRD3 852/4885KCNH2 1997/4885 |
| US-20070093519-A1 | ANTI-EMETIC USES OF CANNABINOID ANALOGS | CNR2, CNR1, FAAH | HRH1 59/4885DRD3 169/4885KCNH2 1507/4885 |
| US-20070099988-A1 | ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS | CNR1, CNR2, HCRTR2 | HRH1 84/4885DRD3 140/4885KCNH2 985/4885 |
| US-20110318425-A1 | TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR, 10aR)- DELTA-8-TETRAHDRAOCANNABINOL-11-OIC ACIDS | CNR1, CNR2, CYSLTR1 | HRH1 328/4885DRD3 635/4885KCNH2 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.